Grace Therapeutics: 10% owner Opaleye Management bought 71,065 shares

What happened

• Opaleye Management Inc., identified as a 10% owner, reported open-market purchases of Grace Therapeutics (GRCE) common stock. The filing lists three purchases: 11,233 shares at $1.93 for $21,735 on Oct 14, 2026; 23,485 shares at $1.95 for $45,685 on Oct 15, 2026; and 36,347 shares at $1.89 for $68,758 on Oct 16, 2026. Total reported purchases equal 71,065 shares for $136,178.

Key details

• Transaction dates and prices:
  • Oct 14, 2026 — 11,233 shares at $1.93 for $21,735 (footnote: weighted-average price range $1.90 to $1.98)
  • Oct 15, 2026 — 23,485 shares at $1.95 for $45,685 (footnote: weighted-average price range $1.90 to $1.95)
  • Oct 16, 2026 — 36,347 shares at $1.89 for $68,758 (footnote: weighted-average price range $1.89 to $1.90)
• Shares owned after the transaction: not reported in this filing.
• Relevant footnotes from the filing:
  • Represents securities owned directly by Opaleye, L.P.; Opaleye Management, Inc. may be deemed to beneficially own those securities as investment manager (F1).
  • Prices are reported as weighted averages; the filer will provide details of the per-trade prices within each reported range upon request (F2, F3, F4).
  • Opaleye Management, Inc. disclaims beneficial ownership except to the extent of its pecuniary interest (F5).
• Filing date: Oct 16, 2026; the filing does not indicate it was late.

Why it may matter

• The filer is reported as a 10% owner, which identifies it as a large holder rather than a company executive.
• A filing does not show why the insider traded or why the company acted.